Close Menu

NEW YORK – NanoString Technologies reported after the close of the market on Wednesday that its second quarter revenues were down 25 percent year over year, driven by lower consumables and collaboration revenues.

For the three months ended June 30, 2020 the company's total revenues were $22.6 million compared to $30.3 million a year ago, beating the consensus Wall Street estimate of $16.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.